Polymerase Chain Reaction (PCR) market is witnessing consistent growth due to its essential role in molecular biology, diagnostics, and research. PCR technology is widely used for DNA amplification, enabling the detection of genetic disorders, infectious diseases, and cancer biomarkers. With increasing demand for rapid and accurate diagnostic tools, the adoption of real-time and digital PCR systems is expanding across clinical and research settings. Technological advancements, rising healthcare investments, and growing awareness of early disease detection are key factors driving the global PCR market forward.
According to Fortune Business Insights, the global polymerase chain reaction (PCR) market was valued at USD 9.15 billion in 2023 and is projected to grow from USD 9.91 billion in 2024 to USD 19.23 billion by 2032, exhibiting a CAGR of 8.6% during the forecast period. In 2023, North America dominated the PCR market with a market share of 40%.
In November 2023, F. Hoffmann‑La Roche Ltd launched the LightCycler PRO System, a next-generation qPCR platform tailored to the evolving demands of molecular diagnostics. This launch marks an advancement in analytical precision, speed, and user-friendly design in clinical settings.